Open AccessDevelopment and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
Author(s) -
Gallen TrianaBaltzer,
Kristof Van Kolen,
Clara Theunis,
Setareh Moughadam,
Randy Slemmon,
Marc Mercken,
Wendy R. Galpern,
Hong Sun,
Hartmuth C. Kolb
Publication year - 2020
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-200463
Subject(s) - cerebrospinal fluid , aka , analyte , epitope , antibody , tau protein , gold standard (test) , chemistry , phosphorylation , computational biology , medicine , microbiology and biotechnology , alzheimer's disease , disease , pathology , biology , immunology , biochemistry , computer science , chromatography , library science
Early and accurate detection and staging is critical to managing Alzheimer's disease (AD) and supporting clinical trials. Cerebrospinal fluid (CSF) biomarkers for amyloid-β peptides, tau species, and various neurodegenerative and inflammatory analytes are leading the way in this regard, yet there is room for improved sensitivity and specificity. In particular tau is known to be present in many different fragments, conformations, and post-translationally modified forms. While the exact tau species that might best reflect AD pathology is unknown, a growing body of evidence suggests that forms with high levels of phosphorylation in the mid-region may be especially enriched in AD.